GENE EXPRESSION PROFILING OF UNKNOWN PRIMARY CANCERS

描述：（申请人的描述） 原发部位不明的癌症是诊断和治疗的难题， 肿瘤学DNA微阵列技术对基因表达的影响 癌症的特征导致了这样的假设，即存在诊断集， 基因，可以解决未知的原发性癌症（UPC）的起源， 高度的信心。这个项目的目的是测试这一点 假设，通过回顾性和前瞻性分析UPC病例 来自斯坦福大学医学中心和萨拉坎农癌症中心， 一个快速发展的基因位点特异性簇数据库的背景 表情具体目的是：（1）基因表达谱的定义 已知的人类癌症。我们现在掌握了大量关于 淋巴瘤、白血病和乳腺癌、前列腺癌、肺癌、卵巢癌，以及 肝脏从我们的肿瘤库和正在进行的样本中累积其他肿瘤 包括肉瘤，生殖细胞癌，黑色素瘤，间皮瘤， 以及结肠癌、胃癌、胰腺癌、膀胱癌和肾癌。（二） 确定每种基因表达的诊断簇， 高于肿瘤类型。我们预计，数百个基因可能会分化 其中之一与其他已知肿瘤不同。(3)获取、基因表达 分析和未知原发癌样本的诊断分类。 这一目标将涉及与世界领先中心的密切合作 对于未知原发性癌症的临床评估，Sarah Cannon 纳什维尔的癌症中心。(4)一组组织特异性 用于UPC标本诊断的抗血清。这一目标将利用 回顾性存档样本以及前瞻性采集样本 从这个项目。(5)特异性或成簇基因表达的鉴定 与已知的预后因素、治疗反应和生存率相关 UPC患者。

DESCRIPTION: (Applicant's Description) Cancers of unknown primary site are a diagnostic and therapeutic dilemma in oncology. Information from DNA micro array technologies on the gene expression profile of cancers has led to the hypothesis that there are diagnostic sets of genes which can resolve the origin of unknown primary cancers (UPC) with a high degree of confidence. The purpose of this project is to test this hypothesis, by both retrospective and prospective analysis of cases of UPC from Stanford Medical Center and the Sarah Cannon Cancer Center, in the context of a rapidly evolving database of site-specific clusters of gene expression. Specific Aims are: (1) Definition of the gene expression profile of known human cancers. We now have extensive information on the profiles of lymphomas, leukemia, and carcinomas of the breast, prostate, lung, ovary, and liver. Additional tumors to be accrued from our tumor bank and ongoing sample acquisitions include sarcomas, germ cell cancers, melanomas, mesotheliomas, and carcinomas of the colon, stomach, pancreas, bladder, and kidney. (2) Determination of the diagnostic cluster of gene expression for each of the above tumor types. We anticipate that several hundred genes may differentiate one from the others of these known tumors. (3) Acquisition, gene expression profiling, and diagnostic classification of unknown primary cancer specimens. This aim will involve a close collaboration with the world's leading center for the clinical evaluation of unknown primary cancers, the Sarah Cannon Cancer Center in Nashville. (4) Evaluation of a panel of histospecific antisera for diagnostic utility with UPC specimens. This aim will utilize retrospective archived specimens as well as prospectively acquired samples from this project. (5) Identification of specific or clustered gene expression associated with known prognostic factors, response to therapies, and survival of patients with UPC.